Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of MK-8644 in Healthy Participants and Plaque Psoriasis Patients
NCT07850310Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing MK-8644 with Placebo (2 arms). Primary endpoints: Number of Participants Who Experience an Adverse Event at 43 days and Number of Participants Who Discontinue Study Due to an Adverse Event at 28 days. Started Oct 2026; status: recruiting.
02
Drugs
MK-8644
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07850310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850310.